Patents by Inventor Basem Al-Shayeb

Basem Al-Shayeb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20240026321
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: May 8, 2023
    Publication date: January 25, 2024
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20230348872
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid. The present disclosure provides methods of detecting a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA.
    Type: Application
    Filed: September 8, 2021
    Publication date: November 2, 2023
    Inventors: Jennifer A. Doudna, Jillian F. Banfield, Basem Al-Shayeb, Patrick Pausch, Katarzyna Soczek
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20230332123
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: June 30, 2023
    Publication date: October 19, 2023
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20230323321
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: November 18, 2022
    Publication date: October 12, 2023
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20230287375
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 14, 2023
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-Cas12J effector polypeptides and methods of use thereof
    Patent number: 11739309
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: August 29, 2023
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-Cas effector polypeptides and methods of use thereof
    Patent number: 11685909
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: June 27, 2023
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR SYSTEMS IN PLANTS
    Publication number: 20230159943
    Abstract: The present disclosure relates to CRISPR-Cas systems that utilize Cas 12J for editing nucleic acids in plants. Methods and compositions for using these systems for editing nucleic acids in plants are provided herein.
    Type: Application
    Filed: April 20, 2021
    Publication date: May 25, 2023
    Applicant: The Regents of the University of California
    Inventors: Steve E. JACOBSEN, Zheng LI, Jennifer DOUDNA, Patrick PAUSH, Basem AL-SHAYEB
  • CRISPR-Cas effector polypeptides and methods of use thereof
    Patent number: 11578313
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: February 14, 2023
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20230028178
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA.
    Type: Application
    Filed: December 22, 2020
    Publication date: January 26, 2023
    Inventors: Jennifer A. Doudna, Jillian F. Banfield, Basem Al-Shayeb
  • CRISPR-Cas effector polypeptides and methods of use thereof
    Patent number: 11530398
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: December 20, 2022
    Assignee: the regents of the university of california
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20220340889
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: May 16, 2022
    Publication date: October 27, 2022
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • Modified cells comprising CRISPR systems
    Patent number: 11377646
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: July 5, 2022
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210403888
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: August 16, 2021
    Publication date: December 30, 2021
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210380957
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA.
    Type: Application
    Filed: August 16, 2021
    Publication date: December 9, 2021
    Inventors: Jennifer A. Doudna, Jillian F. Banfield, Basem Al-Shayeb
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210324358
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: May 5, 2021
    Publication date: October 21, 2021
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210324356
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: April 8, 2021
    Publication date: October 21, 2021
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210317447
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210317428
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: April 8, 2021
    Publication date: October 14, 2021
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch
  • CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20210301271
    Abstract: The present disclosure provides RNA-guided CRISPR-Cas effector proteins, nucleic acids encoding same, and compositions comprising same. The present disclosure provides ribonucleoprotein complexes comprising: an RNA-guided CRISPR-Cas effector protein of the present disclosure; and a guide RNA. The present disclosure provides methods of modifying a target nucleic acid, using an RNA-guided CRISPR-Cas effector protein of the present disclosure and a guide RNA. The present disclosure provides methods of modulating transcription of a target nucleic acid.
    Type: Application
    Filed: April 8, 2021
    Publication date: September 30, 2021
    Inventors: Jennifer A. Doudna, Basem Al-Shayeb, Jillian F. Banfield, Patrick Pausch